Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of TY-9591 with Itraconazole and Rifampicin in Healthy Subjects
NCT06255951Phase 1Completed
- Sponsor
- TYK Medicines
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of asandeutertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by TYK Medicines. Primary endpoints: Peak Plasma Concentration at 6 months, Area Under the Concentration-Time Curve from 0 to Last Quantifiable Time Point at 6 months and 1 more. Started Mar 2024; status: completed.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06255951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255951.